Navigation Links
BioAtom Inc. To Present at BIOCOM Investor Conference 2008
Date:10/26/2008

SAN DIEGO, Oct. 27 /PRNewswire/ -- BioAtom Inc. (private) announced today that it will present at the 3rd annual BIOCOM Investor Conference on Tuesday, October 28, 2008 at 2:30 PM PDT (5:30 PM EDT) at the Hyatt Regency La Jolla in San Diego, California.

Myron Karasik, M.B.A., C.M.C., Director of Finance, will present an overview of Medical Division of BioAtom Inc. of Costa Mesa, CA, dedicated to development and commercialization of Neutron Cancer Diagnostics. Its ONCOSENSOR(TM), a nanotechnology probe, will undergo in vivo evaluation at Center for Functional Onco Imaging, UC Irvine, in collaboration with Radiation Oncology Group, Long Beach Memorial Hospital.

From Bomb Detector to Cancer Diagnostic Probe. Malignant tumors are chemically different from normal tissue. ONCOSENZOR(TM) can non-invasively detect in vitro chemical differences as small as 1 atom/molecule. Its core technology was developed under US Army contracts for non-intrusive detectors of bioagents and explosives in a previous company (no longer in existence), by co-founders of BioAtom, at a cost to shareholders of over $40 million.

Our mission is to provide an early warning, walk-in, painless (non-invasive) and "instant" (online) cancer diagnosis aid that is a quantum leap ahead of competing firms. Operating in tandem with any one of the imaging probes, we hope to ultimately achieve needle-less biopsy. The method has the potential for forewarning of stroke, Alzheimer, and cardiovascular diseases.

Marketing of ONCOSENZOR(TM) to animal clinics, a $13 Billion/year market, does not require FDA approval.

Anna Radovic, Ph.D., 36, President and Chief Scientific Officer, an international cancer researcher and co-patentee, was first to irradiate DNA by neutrons. Christian Druey, B.E.E., 38, has been instrumental in commercialization of medical imaging and explosive detection devices. Bogdan Maglich, Ph.D., CTO and Chairman, the inventor of the core technology, has been elected one of "50 Champions of Innovation" worldwide.

TV interviews: (1) http://www.bioatominc.com (2006); (2) http://www.yourcancertoday.com, (2007) season 2 episode 7. Company has no general non-NDA website as a matter of proprietary policy.

Safe Harbor Statement

This press release contains certain forward-looking statements and projections which include, but are not limited to, references to BioAtom's technology, strategy, and ability to commercialize a novel diagnostic aid. Uncertainties and other factors may cause the actual results to materially differ from those predicted. BioAtom does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioAtom Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to present at BIO Investor Forum 2008
2. China Yingxia to Present at Rodman & Renshaw Annual Global Investment Conference
3. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
9. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
10. Rosetta Genomics to Present at the Upcoming EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"
11. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):